Albumin-based nanocarriers for therapeutic applications
Polymeric Nanosystems, Page: 521-549
2023
- 1Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Albumin has gained much attention as a potential nanocarrier in clinical settings for various therapeutic applications. This could be attributed to the versatile nature, reduced toxicity, and immunogenicity, efficient targeted drug delivery, ability to conjugate with a variety of functional ligands owing to the presence of multiple active binding sites, etc. So far, several albumin-based nanomedicines have been commercialized successfully. This chapter focuses briefly on the different types of nanocarriers that are being extensively researched and the various therapeutic applications that exploit the versatile multifunctional nature of albumin. The review also highlights some of the clinically approved and commercialized albumin-based nanomedicines and those under clinical trials.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780323856560000024; http://dx.doi.org/10.1016/b978-0-323-85656-0.00002-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160166301&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780323856560000024; https://dx.doi.org/10.1016/b978-0-323-85656-0.00002-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know